All In Biotech

Drug Trial Radar · NCT07349212

UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 18, 2026

Primary completion

Mar 1, 2027

Study completion Nov 1, 2027

Sponsor

Lead sponsor
Ukko IncIndustry
Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.

Conditions

  • Peanut-Induced Anaphylaxis
  • Peanut Allergy

Interventions

  • UKK-0018Biological

    UKK0018 is an immunotherapeutic treatment of peanut allergies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of solicited local and systemic adverse reactionsTime frame: 7 days after each injection
  2. To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of unsolicited adverse eventsTime frame: 28 days after each injection
  3. To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of medically-attended adverse events (MAAEsTime frame: 30 weeks after first injection
  4. To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of adverse events of special interest (AESI)Time frame: 30 weeks after first injection
  5. To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of serious adverse events (SAE)Time frame: 30 weeks after first injection

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • St Vincents Hospital

    Darlinghurst, New South Wales, Australia · Recruiting

  • Flinders Medical Center

    Bedford Park, South Australia, Australia · Not yet recruiting

  • The Royal Melbourne Hospital

    Fitzroy, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Perth, Western Australia, Australia · Recruiting

  • Pacific Clinical Research Network - Auckland

    Takapuna, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.